4DMedical Launches CLEAR Clinical Program to Target $3 Billion Pulmonary Embolism Market

MT Newswires Live

Jun 02

4DMedical (ASX:4DX) launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.

The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.

4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2640998020"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640998020\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640998020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640998020","market":"nz","top_or_hot":-1,"title":"4DMedical Launches CLEAR Clinical Program to Target $3 Billion Pulmonary Embolism Market","media":"MT Newswires Live","content":"<html><body><p> 4DMedical (ASX:4DX) launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.</p><p>The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.</p><p>4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4DMedical Launches CLEAR Clinical Program to Target $3 Billion Pulmonary Embolism Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4DMedical Launches CLEAR Clinical Program to Target $3 Billion Pulmonary Embolism Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-02 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> 4DMedical (ASX:4DX) launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.</p><p>The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.</p><p>4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640998020","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640998020","pubTimestamp":1780359607,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"4DMedical  launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","4DX.AU":"4DMEDICAL LTD"},"translate_title":"4DMedical推出CLEAR临床计划瞄准30亿美元肺栓塞市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1},"content_text":"4DMedical (ASX:4DX) launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}